See more : Chandra Prabhu International Ltd. (CHANDRAP.BO) Income Statement Analysis – Financial Results
Complete financial analysis of HeartBeam, Inc. (BEAT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HeartBeam, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Tyler Technologies, Inc. (TYL) Income Statement Analysis – Financial Results
- Beijing Fourth Paradigm Tech (6682.HK) Income Statement Analysis – Financial Results
- Halo Food Co. Limited (HLF.AX) Income Statement Analysis – Financial Results
- Dalata Hotel Group plc (DLTTF) Income Statement Analysis – Financial Results
- Aarti Industries Limited (AARTIIND.BO) Income Statement Analysis – Financial Results
HeartBeam, Inc. (BEAT)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.heartbeam.com
About HeartBeam, Inc.
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 399.47M | 286.78M | 208.33M | 178.51M | 166.58M | 129.50M | 111.49M | 119.02M | 119.92M | 140.62M | 120.45M | 72.99M | 33.92M | 30.94M | 22.23M | 7.92M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 148.99M | 114.41M | 78.88M | 71.96M | 73.11M | 50.43M | 45.59M | 49.08M | 47.49M | 48.69M | 39.91M | 25.53M | 12.70M | 0.00 | 16.97M | 5.66M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 250.49M | 172.37M | 129.45M | 106.56M | 93.46M | 79.07M | 65.90M | 69.95M | 72.43M | 91.93M | 80.54M | 47.47M | 21.22M | 30.94M | 5.26M | 2.26M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 62.70% | 60.11% | 62.14% | 59.69% | 56.11% | 61.06% | 59.11% | 58.77% | 60.40% | 65.38% | 66.86% | 65.03% | 62.56% | 100.00% | 23.66% | 28.51% |
| Research & Development | 6.80M | 5.68M | 255.00K | 133.00K | 41.00K | 11.21M | 11.10M | 8.36M | 7.11M | 7.40M | 7.34M | 4.66M | 5.70M | 4.90M | 5.81M | 4.00M | 3.78M | 3.63M | 0.00 | 2.41M | 4.44M |
| General & Administrative | 8.52M | 7.35M | 2.03M | 655.00K | 0.00 | 112.43M | 88.60M | 56.60M | 47.93M | 45.80M | 37.06M | 33.42M | 35.01M | 34.66M | 39.15M | 41.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.85M | 35.32M | 28.64M | 27.94M | 28.81M | 26.28M | 25.60M | 27.82M | 29.34M | 34.66M | 21.11M | 0.00 | 0.00 | 0.00 | 7.70M | 3.53M |
| SG&A | 8.52M | 7.35M | 2.03M | 655.00K | 253.00K | 155.28M | 123.92M | 85.23M | 75.87M | 74.61M | 63.34M | 59.03M | 62.83M | 64.00M | 73.81M | 63.03M | 0.00 | 0.00 | 0.00 | 7.70M | 3.53M |
| Other Expenses | 0.00 | 3.00K | 22.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.08M | 18.58M | 19.98M | -1.06M | 43.44M | 22.08M | 0.00 | 15.25M | 7.02M |
| Operating Expenses | 15.31M | 13.03M | 2.29M | 788.00K | 294.00K | 166.48M | 135.02M | 93.59M | 82.98M | 82.00M | 70.67M | 63.69M | 80.61M | 87.47M | 99.60M | 65.97M | 47.22M | 25.71M | 0.00 | 25.36M | 14.99M |
| Cost & Expenses | 15.31M | 13.03M | 2.29M | 788.00K | 294.00K | 315.47M | 249.43M | 172.47M | 154.94M | 155.12M | 121.11M | 109.28M | 129.69M | 134.96M | 148.29M | 105.88M | 72.75M | 38.41M | 0.00 | 42.33M | 20.65M |
| Interest Income | 675.00K | 66.00K | 2.17K | 280.00 | 242.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 66.00K | 2.17M | 280.00K | 242.00K | 9.43M | 4.90M | 0.00 | 0.00 | 0.00 | 0.00 | 299.00K | 0.00 | 3.00K | 12.00K | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 15.31M | 13.03M | 2.29M | 788.00K | 294.00K | 40.17M | 28.56M | 14.27M | 12.49M | 12.55M | 12.32M | 9.38M | 12.13M | 12.07M | 10.94M | 8.69M | 4.55M | 2.66M | -42.40M | -848.00K | 46.00K |
| EBITDA | 675.00K | -13.03M | 0.00 | -788.00K | -294.00K | 92.05M | 24.25M | 30.04M | 20.38M | 444.00K | 5.21M | -3.43M | -49.05M | -7.52M | -9.52M | 19.55M | 4.19M | -4.99M | -11.46M | -20.95M | -12.68M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23.04% | 8.46% | 14.42% | 11.42% | 0.27% | 4.03% | -3.08% | -41.21% | -6.27% | -6.77% | 16.23% | 5.74% | -14.71% | -37.05% | -94.22% | -160.04% |
| Operating Income | -15.31M | -13.03M | -2.29M | -788.00K | -294.00K | 84.00M | 37.35M | 35.86M | 23.58M | 11.46M | 8.40M | 2.21M | -10.66M | -15.04M | -7.67M | 14.57M | 241.61K | -4.49M | 30.94M | -20.10M | -12.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 21.03% | 13.02% | 17.21% | 13.21% | 6.88% | 6.48% | 1.98% | -8.96% | -12.54% | -5.45% | 12.10% | 0.33% | -13.23% | 100.00% | -90.41% | -160.62% |
| Total Other Income/Expenses | 675.00K | 69.00K | -2.14M | -280.00K | -242.00K | -42.50M | -47.75M | -20.09M | -15.68M | -23.57M | -15.50M | -15.32M | -50.51M | -4.56M | -12.80M | -3.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -14.64M | -12.96M | -4.43M | -1.07M | -536.00K | 41.50M | -10.40M | 15.77M | 7.90M | -12.11M | -7.10M | -13.11M | -61.18M | -19.60M | -20.47M | 10.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.39% | -3.63% | 7.57% | 4.42% | -7.27% | -5.49% | -11.76% | -51.40% | -16.34% | -14.56% | 8.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -135.00K | 2.17M | 280.00K | 242.00K | -370.00K | 6.75M | -37.67M | 468.00K | -2.31M | 215.00K | -905.00K | 244.00K | 262.00K | 5.00K | 1.48M | 0.00 | 0.00 | 42.40M | 848.00K | -46.00K |
| Net Income | -14.64M | -12.83M | -6.59M | -1.35M | -778.00K | 42.82M | -15.96M | 53.44M | 7.43M | -9.79M | -7.32M | -12.20M | -61.42M | -19.86M | -20.48M | 9.21M | -358.07K | -7.64M | -11.46M | -20.95M | -12.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.72% | -5.56% | 25.65% | 4.16% | -5.88% | -5.65% | -10.94% | -51.61% | -16.56% | -14.56% | 7.64% | -0.49% | -22.54% | -37.05% | -94.22% | -160.04% |
| EPS | -0.72 | -1.57 | -0.84 | -0.17 | -0.10 | 1.20 | -0.53 | 1.91 | 0.27 | -0.37 | -0.29 | -0.49 | -2.51 | -0.82 | -0.86 | 0.50 | -0.12 | -2.63 | -4.04 | -7.33 | -5.23 |
| EPS Diluted | -0.72 | -1.57 | -0.84 | -0.17 | -0.10 | 1.20 | -0.53 | 1.75 | 0.26 | -0.37 | -0.29 | -0.49 | -2.51 | -0.82 | -0.86 | 0.41 | -0.12 | -2.63 | -4.04 | -7.33 | -5.23 |
| Weighted Avg Shares Out | 20.33M | 8.17M | 7.81M | 8.17M | 8.17M | 35.78M | 30.39M | 27.92M | 27.12M | 26.45M | 25.54M | 24.93M | 24.43M | 24.11M | 23.77M | 18.35M | 2.91M | 2.91M | 2.84M | 2.86M | 2.42M |
| Weighted Avg Shares Out (Dil) | 20.33M | 8.17M | 7.81M | 8.17M | 8.17M | 35.78M | 30.39M | 30.49M | 29.09M | 26.45M | 25.54M | 24.93M | 24.43M | 24.11M | 23.77M | 22.66M | 2.91M | 2.91M | 2.84M | 2.86M | 2.42M |
HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference.
HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript
HeartBeam, Inc. (NASDAQ:BEAT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Rob Eno - Chief Executive Officer Branislav Vajdic - President and Founder Tim Cruickshank - Chief Financial Officer Conference Call Participants Operator Greetings,...
HeartBeam Reports Third Quarter 2024 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Third Quarter 2024 Results.
HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time.
HeartBeam Named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards.
HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization.
HeartBeam, Inc. (BEAT) Q2 2024 Earnings Call Transcript
HeartBeam, Inc. (NASDAQ:BEAT ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Branislav Vajdic - Founder and CEO Rob Eno - President Ravi Malhotra - Senior Director, Corporate Controller Conference Call Participants Operator Greetings, and...
Epitel Announces Appointment of Wearables Industry Leader Ken Nelson to Board of Directors
SALT LAKE CITY--(BUSINESS WIRE)--Epitel, a leader in AI technologies for patient-focused brain health solutions, announced today the addition of wearables industry pioneer Ken Nelson to its Board of Directors. With his extensive experience in digital health, medical devices, and remote...
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
- Data continue to support revumenib's potential to enhance current standard of care agents - - 96% CRc (23 of 24 pts) observed in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML...
HeartBeam's Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam's Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias.
Source: https://incomestatements.info
Category: Stock Reports